Survival is not the same as health
Surviving cancer has become increasingly possible, yet the victory carries an unforeseen burden: new research following more than 15,000 older adults finds that those who overcome cancer face roughly twice the risk of developing heart disease compared to those who never received a diagnosis. The treatments that save lives — particularly chemotherapy — appear to exact a toll on the cardiovascular system, with the highest dangers falling on those whose cancers had spread or entered the blood. This is not a counsel of despair, but a call to widen the circle of care, recognizing that healing one system must not mean abandoning another.
- Cancer survivors aged 75 and older are experiencing cardiovascular events — heart attacks, strokes, heart failure — at more than double the rate of their cancer-free peers, a gap that persists even after accounting for traditional risk factors.
- Patients with metastatic, blood, and lung cancers face the steepest climb, with cardiovascular risk rising as high as five times that of the general population, driven in part by more aggressive and toxic treatment regimens.
- Chemotherapy doubles cardiovascular risk on its own, while the one agent long assumed to offer protection — aspirin — proved ineffective in this population, dismantling a common clinical assumption.
- The danger is not static: heart attack and heart failure risk peaks in the first year post-treatment, while stroke risk builds more slowly, cresting after year three and continuing to rise — demanding vigilance long after the cancer itself is gone.
- Cardiac screening and risk management protocols exist and could meaningfully reduce this mortality burden, yet they remain inconsistently applied across cancer care, leaving a survivable gap between what medicine knows and what patients receive.
A cancer diagnosis is survivable now in ways it simply was not a generation ago. But a large new study — tracking more than 15,000 older adults enrolled in the ASPREE trial, with a median age of 74 — reveals that survival and health are not the same thing. Among the roughly 1,400 participants who received a cancer diagnosis during the study period, cardiovascular events occurred at more than double the rate seen in cancer-free peers: 20.8 events per thousand person-years versus 10.3. The gap held firm even after controlling for smoking, blood pressure, and cholesterol.
The risk was not evenly distributed. Metastatic cancers — those that had spread beyond their origin — carried a five-fold increase in cardiovascular danger. Blood cancers showed a similar spike; lung cancers tripled the risk. The most common diagnoses in the cohort were prostate, colorectal, breast, and blood cancers, and more than 80 percent of those diagnosed received some form of treatment.
Chemotherapy emerged as a significant driver of cardiac harm, doubling cardiovascular risk on its own — a finding consistent with what is known about certain drugs damaging heart muscle and blood vessels. Surgery, by contrast, was associated with reduced risk, likely because surgical candidates tended to be healthier at baseline and because removing a tumor eliminates a source of ongoing systemic stress. Aspirin, long assumed to offer cardiac protection, showed no benefit in this population — a result that aligns with growing evidence that its protective effects in older adults have been overstated.
The timing of risk carried its own texture. Heart attack and heart failure dangers peaked in the first year after treatment, then eased. Stroke risk was more patient, remaining stable before climbing sharply after year three. Men faced greater post-treatment cardiovascular risk than women; the oldest patients showed rising risk over time, more pronounced than in the cancer-free group.
The study's authors are clear that this vulnerability is not a sentence. Cardiac screening before and during treatment, careful monitoring of heart function, and management of existing risk factors could prevent or catch much of this damage early. The obstacle is not knowledge — it is translation: ensuring that the older adults who survive cancer also receive the sustained cardiac attention their new circumstances demand.
A cancer diagnosis is supposed to be survivable now. Better drugs, better detection, better outcomes—the survival rates have climbed steadily for decades. But survival, it turns out, is not the same as health. New research tracking more than 15,000 older adults reveals a hard truth: those who beat cancer face roughly double the risk of developing heart disease compared to people who never had cancer at all. For some cancer types, the risk climbs even higher.
The study, published in the journal Cancer, drew its data from the ASPREE trial, a long-running investigation that followed Australian and American patients with a median age of 74. Among the 1,392 participants who received a cancer diagnosis during the study period, the pattern was unmistakable. For every thousand person-years of follow-up, cancer survivors experienced 20.8 cardiovascular events—heart attacks, strokes, hospitalizations for heart failure—compared to just 10.3 events among those without cancer. The increased risk held steady even after researchers accounted for traditional heart disease risk factors like smoking, high blood pressure, and cholesterol.
Not all cancers carried equal danger. Patients with metastatic disease—cancer that had spread beyond its original site—faced a five-fold spike in cardiovascular risk. Blood cancers and lung cancers showed similar escalation, with five-fold and three-fold increases respectively. The study cohort reflected common cancer patterns: prostate cancer affected 26 percent of participants, colorectal cancer 14 percent, breast and blood cancers 12 percent each, and lung and melanoma cancers 8 percent each. Over 80 percent of those diagnosed received treatment, with 55 percent undergoing surgery, 45 percent receiving chemotherapy, and 29 percent radiation therapy.
The drugs themselves appeared to be part of the problem. Chemotherapy, the aggressive chemical assault on cancer cells, doubled the risk of cardiovascular disease. This makes a grim kind of sense: the medications that kill cancer cells can also damage the heart muscle and blood vessels. Patients with metastatic disease, which typically demands higher drug doses or more toxic compounds, bore the heaviest burden. Yet surgery told a different story. Patients who underwent surgical removal of their tumors actually showed reduced cardiovascular risk, possibly because they tended to be healthier at baseline and because removing the tumor itself eliminated a source of systemic stress.
The timing of risk mattered too. For heart attacks and heart failure hospitalizations, the danger spiked in the first year after cancer treatment and then gradually declined. Stroke risk followed a different trajectory, remaining relatively stable until year three, then climbing more steeply than in the cancer-free population. Men faced greater cardiovascular risk than women in the years following treatment. Patients aged 75 and older—the oldest members of the cohort—showed rising risk over time, a pattern that held true whether they had cancer or not, but was more pronounced in the cancer group.
One finding surprised researchers: aspirin, long considered a protective agent against heart disease, offered no benefit to cancer survivors. Both the group taking aspirin and the placebo group experienced similar rates of cardiovascular events. This aligns with recent evidence suggesting that aspirin's protective effects in healthy older adults are weaker than once believed.
The study's authors emphasize that this increased risk, while substantial, is not inevitable. With appropriate cardiac screening before and during cancer treatment, with careful monitoring of heart function, with strategies to manage traditional risk factors, and with encouragement of physical activity, much of the cardiovascular damage could be prevented or caught early. Yet these monitoring protocols remain inconsistently applied across cancer care. The challenge now is translating research into routine practice—ensuring that every older adult who survives cancer also gets the cardiac vigilance their new vulnerability demands.
Notable Quotes
With appropriate screening and management, cardiovascular risk in cancer survivors can be mitigated— Study authors
The Hearth Conversation Another angle on the story
Why does chemotherapy damage the heart? Is it just collateral damage from a drug designed to kill cancer cells?
Partly, yes. Chemotherapy drugs are cytotoxic—they're designed to be poisonous to rapidly dividing cells. Cancer cells divide fast, but so do some heart cells, especially in the muscle tissue. The drugs can scar the heart muscle, weaken its contractions, damage blood vessels. It's not an accident; it's baked into how these drugs work.
But surgery actually reduces cardiovascular risk. How does cutting out a tumor protect the heart?
It's twofold. First, the patients who get surgery tend to be healthier and more fit to begin with—they're the ones whose cancer is localized and operable. Second, the tumor itself is a source of inflammation and metabolic stress on the whole body. Remove it, and you remove that burden. The body can recover.
The study found that risk peaks in year one for heart attacks but doesn't spike for strokes until year three. Why the different timeline?
That's still being understood, but the mechanisms are different. A heart attack often follows acute damage to the heart muscle or sudden blood clots—things that happen quickly after chemotherapy exposure. Stroke risk involves longer-term vascular changes, inflammation in the brain's blood vessels. Those take time to develop.
Aspirin didn't help. That's surprising, given how much we've relied on it for heart protection.
It is surprising, but it fits a larger pattern. Aspirin works well for people who've already had a heart attack or stroke—secondary prevention. For healthy people trying to prevent a first event, the evidence has always been weaker. These cancer survivors are a specific population: older, with particular vulnerabilities. Aspirin just wasn't the answer for them.
What should a 76-year-old cancer survivor do right now?
Get their heart checked. Echocardiogram, stress test, regular monitoring. Know their blood pressure, cholesterol, blood sugar. Move their body. And make sure their oncologist and cardiologist are talking to each other. That last part almost never happens routinely, but it should.